Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
T he MAA seeks approval of tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma MUNICH, GERMANY / ACCESSWIRE / May 20, 2020 / MorphoSys AG (FSE:MOR) Prime Standard Segment; MDAX & TecDAX;...
- The MAA seeks approval of tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma Incyte (NASDAQ:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced...
After four abstracts were released highlighting the latest data on its lead drug candidate, imetelstat, shares of Geron (NASDAQ: GERN) were trading 23.4% higher as of 1:21 p.m. EST on Friday. Previously, Geron's prospects were dealt a significant blow when former imetelstat co-d...
Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from clinical trials of medicines that are being developed in-house and through partnerships with Novartis, MorphoSys and Takeda will be presented at the upcoming 2020 American Society of Clinical Oncology Virtual...
MorphoSys AG ( MOR +2.5% ) and collaboration partner Incyte ( INCY -2.2% ) announce two-year follow-up data from a Phase 2 clinical trial, L-MIND , evaluating the combination of tafasitamab and lenalidomide (branded as Revlimid by Celgene) in patients with relapsed/refractory diffuse ...
Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...
Incyte ( INCY -1.9% ) announces that the FDA has approved exclusive licensee Novartis' ( NVS +1.2% ) Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as...
- Tabrecta is the first and only U.S. Food and Drug Administration (FDA)-approved treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14) - Tabrecta is the fourth molecule discovered by Incyte scientis...
Image source: The Motley Fool. Incyte Corp (NASDAQ: INCY) Q1 2020 Earnings Call May 5, 2020 , 8:00 a.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...